**BREATHER (PENTA 16)**

**BRE**aks in Adolescent and Child **TH**erapy using **Efavirenz** and two **nRTIs**

Phase II randomised trial to determine whether young people can maintain virological suppression during **Short Cycle Therapy (SCT)** (5 days on/2 off)

March 2011 – July 2014

Karina Butler on behalf of PENTA

(Paediatric European Network for the Treatment of AIDS)
Disclosures

Karina Butler
has no financial disclosures
Background & Rationale

• Aims of HIV treatment:
  – Maximise the benefit of ARVs/Minimise long-term toxicity
  – Maintain long-term adherence to prevent resistance and preserve future treatment options

• Challenges facing young people
  – Lifelong therapy
  – Adherence, including the social dimension (eg medication stigma, sleepovers, socialising at weekends, pill fatigue)

➤ Need for new treatment strategies

One Possible Option:
Short Cycle Therapy (SCT): 5 days on treatment / 2 days off
  – Simplification with less toxicity
  – Better adherence
  – Cost savings
BREATHER: Global, Phase II, Randomised, Multi-center, Non-inferiority Trial

Hypothesis: SCT is as efficacious as CT on EFV based 1st line therapy.

Population: Aged 8 to 24 yrs, stable VL <50c/ml on EFV+2NRTI
• No previous virologic failure on a HAART regimen
• CD4 count ≥350 cells/µL at screening visit

Primary Outcome: Time to VL failure (HIV-1 RNA ≥50 c/ml, confirmed) over 48 wks

Pre-defined non inferiority margin: 12% for the difference in failure rate between SCT and CT by week 48 (Kaplan-Meier), adjusted for age & geographic region

Secondary outcomes:
• HIV < 50c/ml at 24 & 48 wks
• Change in CD4 at 24 & 48 wks
• New B, C events or death
• Adherence & acceptability over 48 wks
• Major HIV mutations
• Toxicities
• Change in ART
199 Young people (YP), 11 countries
35% Uganda, 18% Thailand, 6% Argentina, 41% US & Europe
(32 in the pilot phase)

Enrolment
March 2011 – June 2013

RANDOMISATION

SCT
99 YP (15 in pilot)
Stop on Friday/Saturday OR Saturday/Sunday.

CT
100 YP (17 in pilot)
Continue taking ART 7 days a week

Study visits – week 4, 12, 24, 36, 48 and every 12 weeks to trial end

Ireland
•
USA
•
Spain
•
Argentina
•
Denmark
•
Ukraine
•
Germany
Belgium
•
Uganda
Thailand
•
UK
### Baseline Characteristics


90% Vertically acquired. 56% Black, 21% White, 19% Asian

<table>
<thead>
<tr>
<th></th>
<th>SCT</th>
<th>CT</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Young people randomised: n</td>
<td>99</td>
<td>100</td>
<td>199</td>
</tr>
<tr>
<td>≥8 years to &lt;13 years: n (%)</td>
<td>38 (38)</td>
<td>39 (39)</td>
<td>77 (39)</td>
</tr>
<tr>
<td>≥13 years to &lt;18 years: n (%)</td>
<td>39 (39)</td>
<td>41 (41)</td>
<td>80 (40)</td>
</tr>
<tr>
<td>≥18 years to &lt;24 years: n (%)</td>
<td>22 (22)</td>
<td>20 (20)</td>
<td>42 (21)</td>
</tr>
<tr>
<td>CDC Stage: n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N/A</td>
<td>41 (41)</td>
<td>35 (35)</td>
<td>76 (38)</td>
</tr>
<tr>
<td>B</td>
<td>45 (45)</td>
<td>43 (43)</td>
<td>88 (44)</td>
</tr>
<tr>
<td>C</td>
<td>13 (13)</td>
<td>21 (21)</td>
<td>34 (17)</td>
</tr>
<tr>
<td>CD4 %: median (IQR)</td>
<td>34.5 (29, 39)</td>
<td>34.0 (30, 38)</td>
<td>34.0 (30, 39)</td>
</tr>
<tr>
<td>CD4 absolute (cells/mm$^3$): median (IQR)</td>
<td>722.5 (581.0, 965.0)</td>
<td>747.3 (575.3, 972.8)</td>
<td>735.0 (575.5, 967.5)</td>
</tr>
</tbody>
</table>

**Follow up:** median 85.7 weeks, with >98% clinic visits attended up to week 48. One lost to follow up by week 48 (relocated)
Adherence to Strategy

Three independent indicators confirmed adherence to strategy

Adherence questionnaires: YP claimed to take >95% of scheduled drugs. No significant differences between arms.

Mean % days on ART: 72.8% for SCT vs 99.8% for CT.

MEMs cap substudy:

Enrolled: 61 YP: (31 SCT, 30 CT)
At 48 wks: 46 YP: (23 SCT, 23 CT)

Median (IQR) cap openings/week
5 (4,5) SCT vs 7 (6,7) CT.

Proportion of cap openings by day of the week

MCV levels (among patients on zidovudine):

MCV significantly lower in SCT vs CT at every visit week suggesting less exposure to ZDV compared to those in the CT arm.
Primary Endpoint: VL ≥50c/ml (confirmed)

<table>
<thead>
<tr>
<th></th>
<th>Number of events</th>
<th>Person years at risk</th>
<th>Estimated probability of failing*</th>
<th>(90% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCT</td>
<td>6</td>
<td>99.5</td>
<td>6.1%</td>
<td>(2.1, 10.2%)</td>
</tr>
<tr>
<td>CT</td>
<td>7</td>
<td>98.8</td>
<td>7.3%</td>
<td>(2.9, 11.7%)</td>
</tr>
<tr>
<td>Difference (SCT-CT)</td>
<td>-1.2%</td>
<td>(-7.3, 4.9%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Results are consistent with non-inferiority of SCT compared to CT

Kaplan-Meier graph adjusted for age and region

Upper bound of difference between survival curves= 4.9%, which lies well inside the non-inferiority margin of 12%
**Secondary Endpoints: Resistance**

<table>
<thead>
<tr>
<th>HIV-1 MAJOR RESISTANCE MUTATIONS</th>
<th>SCT n/N</th>
<th>CT n/N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sequence available/Virologic Failure</td>
<td>3/6</td>
<td>6/7</td>
</tr>
<tr>
<td>Resistance: Any Class</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NNRTI</td>
<td>2/3</td>
<td>5/6</td>
</tr>
<tr>
<td>NNRTI &amp; NRTI (M184)</td>
<td>1/3</td>
<td>4/6</td>
</tr>
<tr>
<td></td>
<td>1/3</td>
<td>1/6</td>
</tr>
</tbody>
</table>

All 4 YP who failed without sequence data **re-suppressed** after reaching the primary endpoint, indicating resistance unlikely.
Secondary Endpoints & Biomarker Substudy

- No significant differences in CD4 or CD8 count or percent
- Overall no difference in lipid profiles
  - Transient increase in LDL cholesterol in SCT at 24 weeks only
- Platelet counts lower in SCT arm at each follow up visit (p<0.05)

- **Biomarker substudy:** There were no differences between arms in 19 biomarkers of inflammation
  - Only borderline difference in D-Dimers in favour SCT (p=0.048)
Changes in ARV Regimen and in Strategy

Regimen Change: 4 changes in SCT arm, compared to 11 in CT arm (p=0.105)

<table>
<thead>
<tr>
<th></th>
<th>SCT</th>
<th>CT</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number still on initial regimen at 48 week assessment: n (%)</td>
<td>95 (96.0)</td>
<td>88 (88.9)</td>
<td>183 (92.0)</td>
</tr>
<tr>
<td>Change in ART regimen</td>
<td>4 (4.0)</td>
<td>11 (11.1)</td>
<td>13 (6.6)</td>
</tr>
<tr>
<td>Unknown – Lost to follow up</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Reasons for ART regimen change:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Toxicity</td>
<td>2</td>
<td>6</td>
<td>8</td>
</tr>
<tr>
<td>Simplification</td>
<td>1</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Compliance</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>VL failure</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

8 Changed Strategy (5 ➔ 7 day ART a week):
- 6 due to reaching the primary endpoint
- 1 due to an AE leading to discontinuation in EFV (gynaecomastia)
- 1, although remaining suppressed, changed from SCT to CT because poor adherence was noted
## Safety

No deaths or CDC stage C events

<table>
<thead>
<tr>
<th></th>
<th>SCT</th>
<th>CT</th>
<th>Total</th>
<th>p value*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>episodes</td>
<td>(YP)</td>
<td>episodes</td>
<td>(YP)</td>
</tr>
<tr>
<td>Grade 3 and 4 AEs</td>
<td>14</td>
<td>(8)</td>
<td>17</td>
<td>(12)</td>
</tr>
<tr>
<td>ART related AEs</td>
<td>2</td>
<td>(2)</td>
<td>16</td>
<td>(8)</td>
</tr>
<tr>
<td>Treatment modifying AEs</td>
<td>1</td>
<td>(1)</td>
<td>1</td>
<td>(1)</td>
</tr>
<tr>
<td>SAEs</td>
<td>7</td>
<td>(6)</td>
<td>6</td>
<td>(3)</td>
</tr>
</tbody>
</table>

*Fisher’s exact test

- No significant differences in terms of number of young people with adverse events
- Some evidence of more ART related AEs in the CT arm than the SCT arm
- The only SAE reported more than once was spontaneous abortion (1 SCT, 1CT)
- Additionally, there were 5 pregnancies (1 SCT, 4 CT)
### Acceptability (answered only by SCT arm)

**Comparison of things people found difficult before vs. during the study.**

<table>
<thead>
<tr>
<th>Issue</th>
<th>Baseline</th>
<th>End of study</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remembering to take meds</td>
<td>21</td>
<td>16</td>
<td>0.424</td>
</tr>
<tr>
<td>Timing of meds</td>
<td>18</td>
<td>14</td>
<td>0.503</td>
</tr>
<tr>
<td>Number of tablets</td>
<td>8</td>
<td>5</td>
<td>0.549</td>
</tr>
<tr>
<td>Size of tablets</td>
<td>9</td>
<td>5</td>
<td>0.388</td>
</tr>
<tr>
<td>Difficulty swallowing</td>
<td>9</td>
<td>3</td>
<td>0.146</td>
</tr>
<tr>
<td>Amount of syrup</td>
<td>1</td>
<td>1</td>
<td>1.000</td>
</tr>
<tr>
<td>Taste of meds</td>
<td>12</td>
<td>7</td>
<td>0.227</td>
</tr>
<tr>
<td>Side effects</td>
<td>10</td>
<td>5</td>
<td>0.302</td>
</tr>
<tr>
<td>Different routine (weekends)</td>
<td>8</td>
<td>2</td>
<td>0.109</td>
</tr>
<tr>
<td>Different routine (week days)</td>
<td>4</td>
<td>2</td>
<td>0.688</td>
</tr>
<tr>
<td>School/college days</td>
<td>5</td>
<td>1</td>
<td>0.125</td>
</tr>
<tr>
<td>School/college holidays</td>
<td>6</td>
<td>4</td>
<td>0.754</td>
</tr>
<tr>
<td>Staying with friends/family</td>
<td>12</td>
<td>17</td>
<td>0.332</td>
</tr>
<tr>
<td>Going out with friends</td>
<td>15</td>
<td>2</td>
<td>0.001</td>
</tr>
<tr>
<td>Other</td>
<td>11</td>
<td>5</td>
<td>0.210</td>
</tr>
</tbody>
</table>

74% young people said SCT made things a lot easier and 16% said a little easier (63% and 16% at baseline).
What did Young People Say?
Breather Social Science SubStudy

40 young people were interviewed about what it was like being in the trial. You said:

To begin with starting and stopping was confusing and made you worry. But once you got used to it and found a routine, you liked it and it was better than always taking medicine.

Some of you said:

Sometimes you forgot to take your medicine when you were supposed to, but you did not always tell your doctor or nurse. This happened before and during the trial, but being in the trial helped some of you to remember.

It made your social life better as you could stay over at friend’s houses and you didn’t worry about having to take medicine.

You sometimes felt side effects from Efavirenz (feeling dizzy, not being able to concentrate or not feeling yourself) and you did not always tell your doctor or nurse about this. Those of you who had the weekend off taking your medicine, felt better on those two days.

• Liked strategy
• Social life better
• Side effects less at week ends
  – these often not previously disclosed
• Time to adjust
• May not be suitable for all

Bernays S, et al personal communication
BREATHER: Conclusions

• 94% of all YP remained virally suppressed, <50c/ml, to 48 weeks (97% <400c/ml)
• Over 48 weeks for SCT vs CT
  – 1% difference in viral suppression in favour of SCT
  – Primary and alternate analyses consistent
• No evidence of major difference in toxicity parameters
  – Except more reported ART related toxicity in CT
• No difference in clinical, immunologic or virological parameters, or in inflammatory biomarkers or major resistance mutations
• 27% reduction in drug exposure
• Acceptability questionnaires favourable towards SCT
• Long term follow up for 2 additional years has commenced

Non-inferiority of VL suppression in young people on EFV-based first line ART was demonstrated for SCT vs CT
Acknowledgements

This trial was sponsored by the Paediatric European Network for Treatment of AIDS (PENTA) Foundation.

Funding for this study was provided by the European Union Seventh Framework Programme (FP7/2007-2013) under EuroCoord grant agreement n° 260694 with support for trial management and clinical sites in the UK and Ireland from the National Institute for Health Research's HTA Programme.

We thank all of the young people, their families, and staff from the centres participating in the BREATHER trial.
Thank You